MedTrace Logo

Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure

NCT00109655 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2008-10-03

No results posted yet for this study

Summary

The main purpose of this research study is to evaluate the safety and dosing of CG0070.

Conditions

  • Carcinoma, Transitional Cell
  • Bladder Neoplasms

Interventions

BIOLOGICAL

Oncolytic adenovirus (serotype 5) - CG0070

Intravesical administration of CG0070 (in suspension) directly into the bladder

Sponsors & Collaborators

  • Cell Genesys

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2008-10-31
Completion
2010-09-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00109655 on ClinicalTrials.gov